Product Description
DA-8031 is a potent and selective serotonin transporter inhibitor developed for the treatment of premature ejaculation. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23968141/)
Mechanisms of Action: SSR Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Obstetric Labor, Premature|Premature Ejaculation
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DA8031_PE_II | P2 |
Unknown status |
Obstetric Labor, Premature|Premature Ejaculation |
2013-04-01 |
|
| DA-8031 | P1 |
Completed |
Healthy Volunteers |
2011-10-01 |